Background: Immunosupressed patients are at high risk of influenza-related complications. Influenza AH1N1 has been hypothesized to induce worse outcomes in patients with malignancies, but after the A(H1N1)pdm09 few publications have analyzed the presentation and complications related to influenza afterward.
| BACKG ROU N D
Influenza viruses can spread rapidly throughout the world during epidemics and yearly seasonal outbreaks in regions with temperate weather. During these outbreaks, 5%-10% of all adults may acquire the disease, causing serious illness in 3-5 million persons each year, and between 250 000 and 500 000 deaths all over the world. 1 In immunocompromised patients, influenza closely parallels the occurrence of the infection in the community, 2 with higher rates of pneumonia and infection-related mortality. [3] [4] [5] [6] [7] [8] [9] In 2009, a new pandemic influenza virus A(H1N1)pdm09 was identified in Mexico, which rapidly spread all over the world. 1, 4, 10 Among general population, infection with the AH1N1 virus is usually associated with mild respiratory disease with little hospitalization or death 7, 8 ; however, it has been reported that influenza AH1N1 infection can cause a more severe disease than the seasonal influenza virus. 2 In Mexico, the AH1N1 virus has been accompanied by higher mortality rates and a cyclic biannual behavior-alternating with the AH3N2 virus. 1 Globally, during the 2009 A(H1N1)pdm09 pandemic, this virus caused 84.1% of all influenza infections, approximately 18 000 deaths and an overall case-fatality rate lower than 0.5%. 3, 7, 10, 11 Patients with cancer and those with immunosuppression are at high risk of influenza-related complications. 1, 6, 12 These patients were particularly prone to develop serious complications and adverse outcomes at the beginning of the A(H1N1)pdm09 pandemic.
The AH1N1 strain has been hypothesized to induce worse outcomes in patients with malignancies. Early studies in patients with hematologic malignancies (HM) and hematopoietic cell transplant demonstrated higher rates of hospital admissions, pneumonia, intensive care unit admissions, and mortality 2, 3, 7, 8, 10 ; nonetheless, there is insufficient evidence on whether this strain induces worse outcomes. 8, 13 Few studies have reported no difference in outcomes when comparing AH1N1 and other types of influenza in patients with cancer. 2, 4, 10 During the peak of influenza season, the rate of pneumonia in patients with cancer varies between 21% and 80%, and fatality rates range from 11% to 38%. 4, 8, 9, [14] [15] [16] Patients with HM and bone marrow transplant remain at high risk of severe influenza infections. 8, 13, 15, 17, 18 The underlying disease, chemotherapy related toxicity, immunosuppression caused by medications and poor vaccination rates are all contributing factors for infection and severe forms of the disease in this subset of patients.
After the A(H1N1)pdm09 pandemic, limited studies on cancer patients were published 5, 8, 15, 16, 19 and very few publications have reported the presentation and complications related to influenza afterward. The aim of this study was to describe the epidemiology, characteristics, and outcomes of influenza of eight consecutive years in a cohort of patients with cancer and to compare the yearly trends for the same time lapse with community acquired influenza data published by the United States' Centers for Disease Control and Prevention (CDC) and Mexico's Influenza Surveillance (SISVEFLU).
| ME THODS

| Setting and design
We conducted a retrospective analysis of patients with cancer and confirmed influenza at the Instituto Nacional de Cancerologia (INCan) during the study period. INCan is a 136-bed referral, teaching hospital for adolescents and adult patients with cancer, in Mexico City. Since the A(H1N1)pdm09 pandemic a prospective surveillance program for patients with influenza-like illness was established, all hospitalized patients and those with a high suspicion of influenza are evaluated by an Infectious Diseases specialist.
| Patients
All patients with solid or HM and laboratory-confirmed influenza who received care at INCan from April 1, 2009, to March 31, 2017, were included.
We searched the influenza database for all patients with cancer and confirmed diagnosis of influenza, along with the electronical medical record of each patient. We collected the following data: demographics (age and gender), comorbidities, underlying malignancy, oncological treatment, clinical presentation, radiologic characteristics, laboratory data, co-infections, antiviral treatment, and outcomes. Multiple Kaplan-Meier survival analysis was performed, and Log-rank test results were included when group comparison was needed. Finally, we used Pearson's correlations to measure associations between the CDC's, SISVELU's, and our own yearly influenza reports. All reported P values were two-sided and set with significance levels at <.05.
| Definitions
| Statistical analysis
| RE SULTS
| Baseline characteristics
We identified 188 patients with laboratory-confirmed influenza during the study period; one patient was reported to have influenza infection in two different years. Median age was 47 years (range 15-79 years), and 99 (52.6%) patients were female. One hundred thirteen patients (60.1%) had a hematologic malignancy, 51 (45.1%) were lymphomas, 32 (28.3%) were leukemia, and 23 (20.3%) were multiple myeloma. Seventy-five patients (39.9%) had a solid malignancy, being From the 114 patients that required hospitalization ( Seven patients also developed bacteremia: Methicillin-Resistant S aureus (MRSA) (n = 2, one of which also had positive blood cultures for S saprophyticus); MDR A baumannii (n = 1); MSSA (n = 1); methicillin-resistant S haemolyticus (n = 1); S epidermidis (n = 1); and
Enterococcus faecium (n = 1). Other infections included: bacterial conjunctivitis (n = 1), herpes zoster (n = 1), and oral candidiasis (n = 1).
Twenty-four (21%) patients, all with influenza-related pneumonia developed a non-infectious complication, being AKI the most common (n = 20, 83.3%); one patient with AKI also developed concurrent rhabdomyolysis; and another patient developed a right basal ganglia stroke during hospitalization.
Twenty-six (22.8%) patients were admitted to the intensive care unit (ICU) and 8 (30.7%) within 24 hours of admission. From the group of patients with influenza-related pneumonia, thirty-three (28.9%) required mechanical ventilation (MV), some of them were ventilated outside the ICU. Patients with HM had higher rates of severe lymphopenia (31% vs 10% P = .023) and neutropenia (24% vs 7% P = .046) ( Table 2 ).
| Outcome analysis
Risk factors associated with pneumonia after adjusting for dyspnea, lymphocytopenia, and creatinine >1.2 mg/dL are shown in Table 3 . 
| Survival analysis
We performed Kaplan-Meier curves on survival at 30 days. Patients with solid malignancies had a greater survival probability than patients with HM, except for patients with leukemia (P < .001) ( Figure 2 ).
F I G U R E 1
Influenza serotypes in the study population 
| Influenza trends
Yearly occurrence of influenza cases reported by the CDC followed a similar trend to that reported by the SISVEFLU in Mexico, with a significant correlation between both data sets (ρ = 0.823, P = .006) ( Figure 4) . Similarly, cases of influenza occurring in our hospital 
| D ISCUSS I ON
In this study, we showed that oncologic patients, particularly, patients with HM had more severe forms of influenza, as has previously been described. 15 They also showed lower probability of survival compared with patients with solid neoplasm. No significant differences between years or subtype of influenza were observed, and influenza A H1N1 was not associated with worse outcomes. The season-to-season variability of influenza is well described, but only a few studies analyzed various consecutive years and outcomes related to influenza in patients with HM and solid tumors.
Symptoms presented by our patients were similar to those described in non-immunosuppressed patients, [3] [4] [5] 7, 11, 13, 15, 20 frequent complaints. Patients with HM presented with more fever than patients with solid tumors.
In this cohort, patients with HM, lower albumin levels, and hypoxia at diagnosis were at an increased risk for LRI in the multivariable analysis. Pneumonia was developed in 43%, with a higher proportion in patients with HM (55% vs 25%) (P < .001). HM patients presented more frequently with severe lymphopenia (HM 31% vs solid malignancies 10%, P = .023) and severe neutropenia (HM 24% vs solid malignancies 7%, P = .046), consistent with data from other series 3, 4, 8, [10] [11] [12] [13] ; however, this association was not significant in the multivariable logistic analysis.
Decreased albumin level has been associated with LRI. 5, 10 In this series, hypoalbuminemia was associated with pneumonia, which in part reflects the chronic and more advanced stage of disease presented in patients with cancer at our Institution. We also found that hypoxia was as an independent risk factor associated with pneumonia, a characteristic that has previously been described in patients with HM. 5 Hypoxia has also been linked with greater mortality 5, 8 ; but in our study, it was not a predictor of death by multivariate analysis. It is difficult to explain the lack of association between hypoxia and mortality but it is probably related to the fact that other variables such as the underlying malignancy and its advanced stage in most patients remained the most important predictors of mortality. Hypoxemia is probably a marker of severe disease, but not a predictor of adverse influenza-related outcomes.
Obesity has been described as a risk factor for influenza, along with severe complications and death. Also, obese patients shed influenza virus for longer periods of time compared with non-obese individuals. 21 In our cohort, although obesity was prevalent, it did not increase the risk of pneumonia or death, but was correlated with dyspnea and hypoxemia, which is consistent with ventilatory dysfunction and increased risk of mechanical ventilation and death. AKI occurred in 20 (17.5%) patients. Although it has been associated with influenza, this complication has not frequently been described in other studies that included patients with cancer. 8 The increased rate of AKI in this series may be part of a spectrum of influenza complications in complex patients with advanced oncologic disease.
Delayed initiation of antiviral therapy has been correlated with pneumonia and mortality. 2, 6, 7, 10, 16 In this analysis, patients that received oseltamivir after 3 days had a greater influenza-related mortality only on the univariate model, but the same variable had no effect on the development of pneumonia. Likewise, in the survival analysis, probability at 30 days was unaffected by the delayed initiation of antiviral therapy; 58.5% of our patients received oseltamivir during the first 3 days of symptoms onset.
Overall, influenza mortality in patients with cancer varies between 22% and 40%. 11, 16 In our cohort, 30-day mortality was 16% (n = 30) and influenza-related mortality was 12.7% (n = 24). Most of these deaths occurred in the HM group (19 vs 5 solid malignancies, P = .041), reflecting the fragility of these severely immunocompromised patients. Different to what was initially reported with influenza AH1N1, mortality was not increased in patients with A(H1N1) pdm09. [2] [3] [4] 7, 8, 10 In this study, AH1N1 was not associated with the development of pneumonia and was only associated with greater mortality in the univariate model. Also, in patients with HM mortality was higher within the AH1N1 group (AH1N1 patients 17 vs non-AH1N1 2, P = .002) while there were no differences in the solid malignancies group. We did not find any differences in survival probability at 30 days when comparing AH1N1 to other influenza types or viral or bacterial co-infections. Patients with lymphoma and multiple myeloma showed the highest mortality. The less frequent occurrence of H3N2 and an almost perfect yearly alternating behavior between AH1N1 clearly deserves a further and more detailed analysis between the association of subtypes found in Mexico and the United States.
Our study has several limitations since it is a single center observational study, and although most data were collected prospectively, the analysis was conducted retrospectively. Despite the fair number of patients with influenza and cancer, and information from 8 years, we still included more patients with influenza AH1N1 than H3N2 or influenza B, which probably decreased the power to find differences between the outcomes caused by the different types of influenza.
Our study might also have some selection bias, as ambulatory patients with mild influenza were probably treated symptomatically with no further testing for influenza. There is also the possibility that patients with mild symptoms requested medical attention in a different health-care facility. Despite these limitations, this series shows the spectrum of influenza in patients with cancer across a long period of time in Mexico since 2009 when A(H1N1)pdm09 showed up in our country; we also compared our data with that of our national and the CDCs' surveillance system, a correlation that shows the annual trends of influenza seen in hospitals from Mexico City, and much likely, those located on the central and northern of Mexico, with temperate climates.
In conclusion, influenza AH1N1 was the dominant serotype of influenza in our patients, as it has been in the country since the A(H1N1) pdm09 pandemic with biannual peaks. SISVEFLU surveillance information was correlated with that of the CDC. Patients with hematologic malignancies had more severe influenza and presented worse outcomes, including a high-associated mortality. Influenza vaccination was low in this cohort despite being recommended in many international and national guidelines. The biannual presentation of influenza AH1N1 in Mexico and the less frequent occurrence of H3N2 compared with other countries deserves further investigation.
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